Background {#Sec1}
==========

Human skeletal muscle stem cells, called satellite cells, are quiescent, but activated in response to muscle injury \[[@CR1]\] and resistance exercise training \[[@CR2]\]. Activation of satellite cells represents a muscle repair mechanism. Upon activation, these cells proliferate and a subpopulation, myoblasts, differentiates and fuses with existing muscle fibers or other differentiating muscle cells \[[@CR3]\], thus contributing to multinucleated muscle fibers. The process, called myogenesis, is strictly controlled by timely expression of a network of myogenic regulatory factors (MRFs), including MYOD, MYF5, MYOG, and MYF6, together with myocyte enhancer factors 2 (MEF2s) \[[@CR4], [@CR5]\]. However, it is possible that novel myogenic factors that regulate differentiation of human myoblasts into myotubes, and consequently muscle cell function, can be discovered. Additionally, although epigenetic mechanisms such as DNA methylation are known to regulate cell differentiation and cell-specific gene expression, the epigenome and transcriptome of human adult myogenesis is far from defined \[[@CR6]--[@CR8]\].

Obesity is a major risk factor for developing muscular insulin resistance, a condition preceding type 2 diabetes \[[@CR9]\], and is associated with decreased relative muscle mass and impaired muscle metabolism \[[@CR10], [@CR11]\]. Satellite cells reside under the basal lamina of the muscle fibers and are thus exposed to the same environmental factors as the muscle fibers. We have previously reported that in vivo properties, including decreased insulin sensitivity and growth factor signaling, are preserved when human satellite cells from obese subjects with type 2 diabetes are isolated and differentiated to myotubes in vitro \[[@CR12]--[@CR14]\]. Therefore, we hypothesized that obesity-dependent epigenetic modifications are established in human satellite cells and potentially affect myogenesis in obese individuals.

Of note, factors such as high fat diet, exercise, and aging have previously been shown to alter the DNA methylation pattern in human skeletal muscle \[[@CR15]--[@CR19]\]. Additionally, muscle biopsies isolated from monozygotic twin pairs discordant for type 2 diabetes and body mass index (BMI) exhibit differential DNA methylation \[[@CR20]\].

Based on this background, we aimed to study changes in the genome-wide DNA methylation and gene expression patterns during human adult myogenesis, i.e. differentiation of activated primary human muscle stem cells (myoblasts) from healthy subjects into myotubes, and also examine if obesity affects the epigenetic and transcriptional changes that take place during this process. To address these questions we (1) studied changes in the genome-wide DNA methylation and expression patterns during differentiation of primary human myoblasts into myotubes in healthy subjects; (2) performed functional follow-up experiments of some identified candidate genes previously not known to affect myogenesis in order to find novel targets that regulate muscle regeneration and function; and (3) examined if the epigenetic and transcriptional changes that take place in human myoblasts during differentiation into myotubes are different in obese compared with non-obese subjects.

Methods {#Sec2}
=======

Primary human muscle stem cell isolation and culture of myoblasts {#Sec3}
-----------------------------------------------------------------

Primary muscle stem cells (satellite cells) were isolated from human vastus lateralis biopsies. Myoblasts were harvested when less than 50% confluent (Additional file [1](#MOESM1){ref-type="media"}: Figure S1A). See Additional file [1](#MOESM1){ref-type="media"}: Supplemental Methods for details of myoblast culture and differentiation.

DNA methylation and mRNA expression arrays {#Sec4}
------------------------------------------

DNA methylation was analyzed using Infinium HumanMethylation450 BeadChip (Illumina, San Diego, CA, USA). mRNA expression was analyzed using HumanHT-12 Expression BeadChip (Illumina). See Additional file [1](#MOESM1){ref-type="media"}: Supplemental Methods for details.

Statistical analysis {#Sec5}
--------------------

Two-tailed t-tests were used to compare clinical characteristics between the groups. Comparison of DNA methylation and expression data between myoblasts and myotubes were analyzed with paired Wilcoxon signed rank tests and for array data adjusted for multiple testing with false discovery rate (FDR) analysis. Spearman correlations were used to correlate gene expression and DNA methylation. Number of correlations expected by chance was calculated as number of tests times 0.05. Data from gene silencing experiments were analyzed with paired t-tests and log-transformed values were used for qPCR data. Mouse data were analyzed with Mann--Whitney U tests. Distributions were analyzed with χ^2^ tests and Bonferroni-corrected when feasible. To compare DNA methylation and mRNA expression array data between non-obese and obese subjects we used a linear regression analysis including obesity, age, and sex as co-variates. A FDR less than 5% (*q* \< 0.05) was applied. See Additional file [1](#MOESM1){ref-type="media"}: Supplemental Methods for more details of materials and methods.

Results {#Sec6}
=======

Human muscle stem cells {#Sec7}
-----------------------

Human muscle stem cells (satellite cells) were isolated from skeletal muscle biopsies obtained from 14 healthy non-obese and 14 obese subjects. Their clinical characteristics are described in Table [1](#Tab1){ref-type="table"}. Isolated satellite cells were expanded and differentiated from myoblasts into myotubes \[[@CR13]\]. Cells were harvested as proliferating myoblasts and as fully differentiated myotubes (Additional file [1](#MOESM1){ref-type="media"}: Figure S1A).Table 1Clinical characteristics of study participantsNon-obese (*N* = 14)Obese (*N* = 14)*P* valueMen/Women7/78/6Age, years54.2 ± 6.850.2 ± 6.21.3 × 10^−1^BMI, kg/m^2^24.7 ± 2.435.1 ± 2.85.1 × 10^−11^Weight, kg74.5 ± 14.2111.3 ± 9.01.2 × 10^−9^Hip circumference, cm100.6 ± 4.7119.6 ± 6.95.7 × 10^−9^Waist circumference, cm85.9 ± 10.2116.1 ± 8.66.2 × 10^−9^Android fat mass, kg1.7 ± 7.14.9 ± 1.04.3 × 10^−10^Gynoid fat mass, kg4.0 ± 1.37.0 ± 2.06.5 × 10^−5^Whole body fat mass, kg20.0 ± 6.042.7 ± 8.71.7 × 10^−8^Whole body fat-free mass, kg51.4 ± 13.363.9 ± 11.91.4 × 10^−2^Fasting glucose, mmol/L4.8 ± 0.65.0 ± 0.42.3 × 10^−1^2-h glucose, mmol/L^a^5.2 ± 1.45.5 ± 1.45.6 × 10^−1^Fasting insulin, pmol/L32.1 ± 13.392.7 ± 30.33.8 × 10^−7^2-h insulin, pmol/L^a^230.1 ± 155.3441.9 ± 287.02.4 × 10^−2^HOMA-IR1.0 ± 0.53.0 ± 1.11.8 × 10^−6^HOMA-β, %74.4 ± 26.7184.4 ± 74.82.4 × 10^−5^P-Cholesterol-total, mmol/L5.5 ± 1.05.2 ± 0.84.3 × 10^−1^P-Cholesterol-HDL, mmol/L1.7 ± 0.51.3 ± 0.31.7 × 10^−2^P-Cholesterol-LDL, mmol/L3.3 ± 0.93.3 ± 0.69.8 × 10^−1^Systolic blood pressure, mmHg134.3 ± 12.0138.5 ± 18.14.7 × 10^−1^Diastolic blood pressure, mmHg85.6 ± 9.591.6 ± 9.19.8 × 10^−1^Pulse, beats/min59.5 ± 12.466.6 ± 8.48.6 × 10^−11^VO~2~ max per kg, mL/min/kg32.6 ± 11.422.2 ± 4.43.8 × 10^−3^Data are presented as mean ± SD. Two-tailed t-tests were used for statistical calculations^a^Measured during a 2-h oral glucose tolerance test

To evaluate myogenic purity of the cultured cells, we assessed their cell surface marker expression by flow cytometry analysis. To discriminate myogenic cells from non-myogenic cells, we used CD56, which is expressed on myogenic cells, and CD31 and CD45, which are expressed on endothelial and hematopoietic cells, respectively \[[@CR21]\]. All cell cultures were negative for CD31 and CD45 and all cell cultures were positive for CD56; there was no significant difference between the non-obese and obese groups in the percentage of gated single cells expressing CD56 (Additional file [1](#MOESM1){ref-type="media"}: Figure S1B--D).

Changes in the global DNA methylation pattern during differentiation of primary human myoblasts into myotubes of healthy subjects {#Sec8}
---------------------------------------------------------------------------------------------------------------------------------

To examine if epigenetic changes take place during human myogenesis, we examined the genome-wide DNA methylation pattern in human myoblasts and myotubes from 14 healthy non-obese subjects using the Infinium HumanMethylation450 BeadChip. An overview of comparisons performed in this study is presented in Fig. [1a](#Fig1){ref-type="fig"}.Fig. 1The human methylome before versus after differentiation of human primary myoblasts. **a** An illustrative description of the study design and comparisons performed in cells of both non-obese and obese subjects. **b** Global DNA methylation was calculated as the average degree of methylation for all analyzed CpG sites before (*n* = 14) and after (*n* = 14) differentiation of myoblasts of non-obese subjects based on Illumina's annotations to different gene regions and CpG island regions. Data are presented as mean ± SEM. Total number of sites per region: TSS1500, 83,650; TSS200, 62,369; 5'UTR, 64,909; 1^st^ Exon, 39,236; Body, 172,275; 3'UTR, 19,349; Intergenic, 116,209. **c** A pie chart showing the number and proportions of individual CpG sites with significantly increased and decreased methylation, respectively, in human myoblasts compared with myotubes (*q* \< 0.05) of non-obese subjects (*n* = 14). **d** Proportions of significant CpG sites with a certain degree of methylation before differentiation compared with the proportions of all analyzed sites. **e** DNA methylation of the three most significant CpG sites annotated to key myogenic transcription factors in human myoblasts versus myotubes of non-obese subjects. **f** Global DNA methylation was calculated as the average degree of methylation for all analyzed non-CpG sites before and after differentiation in non-obese subjects based on Illumina's annotations to different gene region and CpG island regions. Data are presented as mean ± SEM. TSS, proximal promoter, defined as 200 bp (base pairs) or 1500 bp upstream of transcription start site; UTR, untranslated region; CpG island, 200 bp (or more) stretch of DNA with a C + G content greater than 50% and an observed CpG/expected CpG in excess of 0.6; Shore, the flanking region of CpG islands, 0--2000 bp; Shelf, regions flanking island shores, i.e., covering 2000--4000 bp distant from the CpG island. \* *q* \< 0.05

After quality control, DNA methylation data were obtained for a total of 477,226 CpG sites in myoblasts and myotubes. The analyzed CpG sites have been annotated to different gene regions based on their genomic location and in relation to CpG islands \[[@CR22]\]. To examine the global methylation level for myoblasts and myotubes, we calculated the average level of DNA methylation in these gene regions (Fig. [1b](#Fig1){ref-type="fig"}). The highest level of methylation (48--63%) was found distant from promoter regions (gene body and 3'UTR) and in intergenic regions, whereas regions close to the transcription start site (TSS1500, TSS200, 5'UTR and 1^st^ exon) were least methylated (12--26%). Interestingly, the average methylation levels for TSS1500, TSS200, 5'UTR and 1^st^ exon were significantly increased after differentiation (q \< 0.05). When investigating global methylation in CpG island regions, the CpG islands (15%) and the shores (36--37%) were least methylated and their average methylation levels increased significantly after differentiation (q \< 0.05). The shelves and the open sea had an average methylation level of approximately 60% and were not altered during myogenesis. Of note, all genomic regions with a relatively low degree of methylation increased significantly after differentiation, suggesting that epigenetic regulation in these regions might play an important role during human myogenesis.

Changes in DNA methylation of individual CpG sites during differentiation of primary human myoblasts into myotubes of healthy subjects {#Sec9}
--------------------------------------------------------------------------------------------------------------------------------------

We next tested if DNA methylation of any individual CpG site changed in myoblasts versus myotubes from the 14 healthy non-obese subjects. Indeed, DNA methylation of a large number of individual CpG sites (39,572) changed significantly during differentiation (FDR less than 5%; q \< 0.05). The significant sites are annotated to 13,639 unique genes and intergenic regions (Additional file [2](#MOESM2){ref-type="media"}: Table S1). Our findings reflect dominant de novo methylation as the majority of these sites (92%, 36,541 sites) had increased methylation, whereas only 8% (3031 sites) had decreased methylation after differentiation (Fig. [1c](#Fig1){ref-type="fig"}). CpG sites with increased methylation after differentiation generally had a low degree of methylation in myoblasts, whereas CpG sites with decreased methylation had a relatively high degree of methylation in myoblasts (Fig. [1d](#Fig1){ref-type="fig"}). The largest absolute change in methylation and fold-change were 16.5% and 2.05, respectively (Additional file [2](#MOESM2){ref-type="media"}: Table S1).

Interestingly, several key myogenic transcription factors, including *PAX7*, MRFs, and MEF2s, had numerous CpG sites with significant changes in DNA methylation before versus after differentiation (Additional file [2](#MOESM2){ref-type="media"}: Table S1), suggesting that changes in DNA methylation contribute to the regulation of human myogenesis. The three most significant CpG sites for each of these myogenic transcription factors are shown in Fig. [1e](#Fig1){ref-type="fig"}. Of note, *PAX7* showed differential methylation of 24 of 81 analyzed CpG sites, all but one with increased methylation, and 7 of 9 analyzed CpG sites annotated to *MYF5* showed significantly increased methylation after differentiation.

We next performed KEGG pathway analysis using Webgestalt \[[@CR23]\] to identify biological pathways with enrichment of genes that exhibited differential DNA methylation during myogenesis. Genes with one or more differentially methylated CpG site(s) were significantly enriched in 27 KEGG-pathways (Table [2](#Tab2){ref-type="table"} and Additional file [2](#MOESM2){ref-type="media"}: Table S1). Among the significant pathways were MAPK signaling, cell cycle, oxidative phosphorylation, regulation of actin cytoskeleton, TGF-β signaling, and calcium signaling, together supporting the development of a functional myotube \[[@CR4]\].Table 2Significantly enriched KEGG pathways among differentially methylated genes between myoblasts and myotubesPathway (total number of genes in pathway)Observed/Expected number of genes*P* value*q* valueNon-obese subjects Pathways in cancer (325)321/2959.8 × 10^−10^2.2 × 10^−7^ Metabolic pathways (1112)1060/10093.3 × 10^−9^3.7 × 10^−7^ Focal adhesion (200)199/1827.6 × 10^−8^4.3 × 10^−6^ Endocytosis (200)199/1827.6 × 10^−8^4.3 × 10^−6^ MAPK signaling pathway (267)260/2421.4 × 10^−5^5.0 × 10^−4^ Ubiquitin mediated proteolysis (134)133/1223.3 × 10^−5^1.1 × 10^−3^ Neurotrophin signaling pathway (127)126/1156.2 × 10^−5^1.8 × 10^−3^ Protein processing in endoplasmic reticulum (165)162/1501.0 × 10^−4^1.8 × 10^−3^ Lysosome (121)120/1101.0 × 10^−4^1.8 × 10^−3^ Cell cycle (124)123/1138.1 × 10^−5^1.8 × 10^−3^ Oxidative phosphorylation (119)118/1081.0 × 10^−4^1.8 × 10^−3^ Regulation of actin cytoskeleton (211)205/1922.0 × 10^−4^2.9 × 10^−3^ TGF-beta signaling pathway (84)84/763.0 × 10^−4^3.8 × 10^−3^ Axon guidance (129)127/1174.0 × 10^−4^4.8 × 10^−3^ Phosphatidylinositol signaling system (78)78/715.0 × 10^−4^5.7 × 10^−3^ Purine metabolism (162)158/1476.0 × 10^−4^6.5 × 10^−3^ Calcium signaling pathway (176)171/1608.0 × 10^−4^7.9 × 10^−3^ Pyrimidine metabolism (98)97/898.0 × 10^−4^7.9 × 10^−3^ Adipocytokine signaling pathway (68)68/621.4 × 10^−3^1.3 × 10^−2^ p53 signaling pathway (68)68/621.4 × 10^−3^1.3 × 10^−2^ Wnt signaling pathway (149)145/1351.5 × 10^−3^1.3 × 10^−2^ ErbB signaling pathway (87)86/792.1 × 10^−3^1.7 × 10^−2^ Melanogenesis (101)99/923.5 × 10^−3^2.6 × 10^−2^ Inositol phosphate metabolism (57)57/524.0 × 10^−3^2.9 × 10^−2^ Peroxisome (79)78/724.3 × 10^−3^3.0 × 10^−2^ mTOR signaling pathway (52)52/476.5 × 10^−3^4.2 × 10^−2^ Spliceosome (127)123/1157.0 × 10^−3^4.4 × 10^−2^Obese subjects Pathways in cancer (325)325/3114.3 × 10^−7^9.8 × 10^−5^ Metabolic pathways (1112)1086/10632.0 × 10^−4^2.3 × 10^−2^

MicroRNA (miRNA) is another epigenetic mechanism known to regulate gene transcription and DNA methylation may further regulate miRNA expression \[[@CR24]\]. A number of miRNAs has also been shown to influence myogenesis \[[@CR25]\]. Here, we found significant methylation changes of 225 CpG sites annotated to 157 different miRNA genes during myogenesis (Additional file [2](#MOESM2){ref-type="media"}: Table S1), including 17 of the 60 miRNA identified by Dmitriev et al. \[[@CR25]\].

Methylation of non-CpG sites during myogenesis {#Sec10}
----------------------------------------------

Although DNA methylation in the human genome mainly takes place on cytosines in CpG sites, cytosines followed by another base than guanine can also be methylated, by the so called non-CpG methylation. Methylation of non-CpG sites has previously been found in stem cells \[[@CR26]\] and we therefore tested if methylation of these sites changed during myogenesis. The average methylation level of the analyzed non-CpG sites increased significantly for all gene and CpG island regions after differentiation (Fig. [1f](#Fig1){ref-type="fig"}). Additionally, methylation of 665 individual non-CpG sites (60% of the analyzed sites) changed significantly and all showed increased methylation after differentiation (*q* \< 0.05) (Additional file [2](#MOESM2){ref-type="media"}: Table S1).

Changes in the transcriptome during differentiation of primary human myoblasts into myotubes of healthy subjects {#Sec11}
----------------------------------------------------------------------------------------------------------------

We proceeded to evaluate the genome-wide transcriptome changes characterizing human myogenesis. Complete mRNA data were obtained from 13 healthy non-obese subjects. We found significant expression changes of a large number of transcripts (7699 with FDR \< 5%) corresponding to 6305 unique genes before versus after differentiation (Additional file [3](#MOESM3){ref-type="media"}: Table S2); 45% of these transcripts were upregulated and 55% were downregulated.

Importantly, several key myogenic transcription factors were differentially expressed between myoblasts and myotubes (Fig. [2a](#Fig2){ref-type="fig"}). For example, *PAX7*, *MYOD1*, *MYF5*, and *MYF6* showed significantly decreased expression, while *MYOG*, *MEF2A*, *MEF2C*, and *MEF2D* showed increased expression after differentiation (Fig. [2a](#Fig2){ref-type="fig"} and Additional file [3](#MOESM3){ref-type="media"}: Table S2). In accordance, all of these genes exhibited differential DNA methylation during myogenesis (Fig. [1e](#Fig1){ref-type="fig"} and Additional file [2](#MOESM2){ref-type="media"}: Table S1).Fig. 2Transcriptional changes before versus after differentiation of human primary myoblasts of non-obese subjects. **a** Significant changes in mRNA expression of key myogenic transcription factors in human myoblasts (*n* = 13) versus myotubes (*n* = 13) of non-obese subjects. Significantly enriched downregulated (**b**) and upregulated (**c**) gene sets in Gene Set Enrichment Analysis with FDR \< 5% (*q* \< 0.05) based on differential gene expression in human myoblasts versus myotubes of non-obese subjects. Significant changes in mRNA expression of genes encoding cell cycle proteins (**d**), myosin heavy and light chains (**e**), proteins in the respiratory chain (**f**), and cytokines and their receptors (**g**) in human myoblasts versus myotubes of non-obese subjects (*n* = 13). Data are presented as mean ± SEM. ECM, Extracellular matrix; Val, Valine; Leu, Leucine; Ile, Isoleucine. \* *q* \< 0.05

To further dissect what cellular events the differentially expressed genes are involved in, Gene Set Enrichment Analysis (GSEA) \[[@CR27]\] was applied. Among downregulated genes, we identified 17 significant gene sets, including gene sets related to DNA replication and nucleotide biosynthesis, i.e., the cell cycle (Fig. [2b](#Fig2){ref-type="fig"} and Additional file [3](#MOESM3){ref-type="media"}: Table S2). Additionally, 25 gene sets were significant among upregulated genes, including extracellular matrix receptor interactions, calcium signaling, and several pathways involved in cellular metabolism (Fig. [2c](#Fig2){ref-type="fig"} and Additional file [3](#MOESM3){ref-type="media"}: Table S2), altogether confirming that the cells developed from proliferating myoblasts into metabolically active myotubes (Additional file [1](#MOESM1){ref-type="media"}: Figure S1A). Notably, many genes regulating the cell cycle (Fig. [2d](#Fig2){ref-type="fig"}) and protein turnover showed significantly altered expression during myogenesis, reflecting withdrawal from the cell cycle before differentiation. The negative regulators of the cell cycle, *CDKN1A* and *CDKN1C*, were upregulated while many cyclins (*CCNA2*, *CCNB1*, *CCNB2*, and *CCNE2*) and cyclin-dependent kinases (*CDK1*, *CDK2*, and *CDK6)* were downregulated after differentiation. Moreover, numerous genes important for muscle contraction, such as myosin light chain (MLC) and heavy chain (MHC) (Fig. [2e](#Fig2){ref-type="fig"}), troponin, and actin, genes regulating storage, release and reuptake of calcium ions, as well as genes involved in oxidative phosphorylation (Fig. [2f](#Fig2){ref-type="fig"}) were upregulated after differentiation.

Since skeletal muscle is an endocrine organ \[[@CR28]\] we also examined if the expression pattern of a number of cytokines, growth factors, and their receptors changed during differentiation (Fig. [2g](#Fig2){ref-type="fig"}). The regulation pattern of these genes may reflect autocrine properties of skeletal muscle cells, which are crucial for muscle repair and development \[[@CR1]\].

Identification of gene families with novel regulation patterns during myogenesis {#Sec12}
--------------------------------------------------------------------------------

Remarkably, we also identified several gene families previously not known to affect myogenesis, including metallothioneins, pregnancy-specific beta-1-glycoproteins (PSGs), and chorionic gonadotropin beta polypeptides (CGBs) (Fig. [3a](#Fig3){ref-type="fig"}--[c](#Fig3){ref-type="fig"}). Interestingly, all significant genes in these families were highly expressed in myoblasts and strongly downregulated after differentiation. While two of the gene families, PSG and CGB, are produced by trophoblasts during pregnancy \[[@CR29], [@CR30]\], their expression has never been reported in myoblasts.Fig. 3Newly identified gene families, transcription factor binding motifs, and overlapping changes in gene expression and DNA methylation before versus after differentiation of human primary myoblasts of non-obese subjects. Significant changes in mRNA expression of genes encoding metallothioneins (**a**), pregnancy-specific beta-1 glycoproteins (**b**), and chorionic gonadotropin beta polypeptides (**c**) in human myoblasts versus myotubes of non-obese subjects (*n* = 13). **d** To the left is mRNA expression of identified transcription factors with significant enrichment of binding motifs in promoter regions of all differentially expressed genes in human myoblasts versus myotubes of non-obese subjects (*n* = 13). Those with a red box are further emphasized to the right in the figure. This figure shows Bonferroni adjusted *P* values and binding motifs for enriched transcription factors in the SP/KLF family and E2F transcription factor family. DNA methylation of the three most significant CpG sites in myoblasts versus myotubes annotated to genes that also showed differential mRNA expression among cell cycle genes (**e**), metallothioneins (**f**), and transcription factors with enriched binding motifs among all differentially expressed genes (**g**) in non-obese subjects (*n* = 14). (See also Figs. [2d](#Fig2){ref-type="fig"}, 3a and d). **h** Increased promoter methylation and reduced expression of *MCM10* during differentiation. **i** In vitro methylation of the *MCM10* promoter resulted in decreased transcriptional activity, measured as luciferase activity (*n* = 4, \*\**P* \< 0.01). Data are presented as mean ± SEM. TF, Transcription factor. \* *q* \< 0.05

Identification of transcription factor binding motifs of importance for myogenesis {#Sec13}
----------------------------------------------------------------------------------

To identify transcription factors potentially driving transcriptional changes during myogenesis, we used PSCAN \[[@CR31]\] and JASPAR \[[@CR32]\]. Here, we searched for overrepresentation of specific transcription factor binding sequences among the differentially expressed genes. Recognition sequences for 48 transcription factors were significantly enriched (*P* ~Bonferroni~ \< 0.05) (Additional file [3](#MOESM3){ref-type="media"}: Table S2) and 18 of these did also themselves show differential expression between myoblasts and myotubes (Fig. [3d](#Fig3){ref-type="fig"}), including members in the SP/KLF family and E2F transcription factor family.

Overlapping changes in DNA methylation and mRNA expression during myogenesis {#Sec14}
----------------------------------------------------------------------------

Epigenetic modifications can affect gene expression \[[@CR33]\]; hence, we looked for genes that had changes in both DNA methylation and expression after differentiation. When comparing myoblasts and myotubes from healthy subjects, 4285 genes had significant differences in both expression and DNA methylation of one or more CpG site(s) (Fig. [1a](#Fig1){ref-type="fig"}, Table [3](#Tab3){ref-type="table"} and Additional file [4](#MOESM4){ref-type="media"}: Table S3). These include the MRFs (Figs. [1e](#Fig1){ref-type="fig"} and [2a](#Fig2){ref-type="fig"}), many of the cell cycle genes (Figs. [2d](#Fig2){ref-type="fig"} and [3e](#Fig3){ref-type="fig"}), metallothioneins (Fig. [3a and f](#Fig3){ref-type="fig"}), and the transcription factors identified with PSCAN (Fig. [3d](#Fig3){ref-type="fig"} and [g](#Fig3){ref-type="fig"}).Table 3Twenty genes with largest fold-change in expression that were also differentially methylated at one or more CpG site before versus after differentiation in non-obeseExpressionDNA methylation (%)IlluminaIDGene symbolMyoblastsMyotubesRatio*q* valueProbe IDGene regionMyoblastsMyotubesDifference*q* valueDownregulated1170300*MT1G*8314.1 ± 5678.0167.0 ± 63.30.020.0017cg035661425′UTR;1stExon13.8 ± 2.517.2 ± 2.63.40.0333710161*LHB*547.1 ± 606.818.3 ± 9.70.030.0017cg06452915TSS15008.8 ± 0.412.2 ± 1.13.50.0291400634*MT1M*2099.9 ± 1709.170.5 ± 33.90.030.0017cg049949645′UTR;1stExon12.7 ± 0.715.2 ± 1.12.50.0264880609*DKK1*767.1 ± 567.573.6 ± 57.50.10.0025cg11988964TSS150013.4 ± 1.119.3 ± 1.75.90.026cg02302582TSS150015.8 ± 1.620.0 ± 1.54.20.031cg27411220TSS150011.0 ± 2.114.5 ± 2.83.50.033cg02493604TSS150012.6 ± 1.617.0 ± 2.34.40.041cg076847961stExon7.6 ± 0.410.3 ± 1.42.60.0496660601*HMOX1*3277.5 ± 1728.4209.7 ± 104.10.10.0017cg057182553′UTR17.9 ± 2.322.4 ± 1.94.50.0496620528*MT1X*7739.1 ± 4215.6624.4 ± 155.50.10.0017cg03551406TSS150032.2 ± 2.036.1 ± 2.33.90.026cg03368362TSS15008.0 ± 0.411.5 ± 1.13.50.033cg05596720TSS2006.8 ± 0.38.6 ± 0.41.70.0262480452*MYF5*1631.4 ± 1200.0130.9 ± 77.60.10.0017cg14952949TSS150025.1 ± 3.232.8 ± 2.67.70.029cg04524478TSS150039.6 ± 4.150.7 ± 3.011.10.033cg14067873TSS20025.7 ± 2.032.2 ± 2.16.50.026cg063765205′UTR;1stExon25.5 ± 2.029.2 ± 1.83.60.044cg262075035′UTR;1stExon25.9 ± 3.033.9 ± 2.58.00.049cg211267071stExon28.7 ± 4.136.3 ± 3.87.60.033cg10868277Body29.7 ± 5.938.5 ± 5.68.80.0353440095*PSG3*588.6 ± 427.367.6 ± 97.40.10.0017cg07745725TSS150048.9 ± 1.151.9 ± 1.62.90.038cg24313473Body14.0 ± 0.917.2 ± 1.53.30.0444480292*PSG5*429.1 ± 283.660.7 ± 97.90.10.0017cg010119435′UTR;1stExon37.5 ± 1.841.3 ± 2.03.80.026cg010119435′UTR;1stExon37.5 ± 1.841.3 ± 2.03.80.026580711*SMAD6*725.9 ± 245.073.0 ± 39.30.10.0017cg12216518TSS1500;Body20.4 ± 1.624.8 ± 2.04.40.035cg178602015′UTR;1stExon;Body73.1 ± 1.578.1 ± 1.45.00.031cg27514333Body13.6 ± 1.817.5 ± 2.23.90.026Upregulated5080132*ACTA1*391.8 ± 893.011408.8 ± 4221.929.10.0025cg20025656TSS150016.4 ± 1.120.8 ± 1.74.50.028cg02970384Body8.8 ± 0.812.0 ± 1.53.20.0381230451*TPM2*147.9 ± 118.35491.1 ± 3076.837.10.0017cg13969788Body25.0 ± 3.930.3 ± 4.15.30.031cg26607748TSS2008.7 ± 0.511.2 ± 0.92.50.0444150379*TNNT3*32.5 ± 42.81258.1 ± 750.438.70.0017cg26355894TSS20012.9 ± 1.816.5 ± 2.73.70.028cg158498725′UTR11.3 ± 0.414.3 ± 0.93.00.028cg16911576Body73.3 ± 1.969.7 ± 2.2−3.70.0444760040*NEB*30.3 ± 33.51195.0 ± 957.839.40.0017cg17254273TSS150081.2 ± 1.277.9 ± 1.2−3.30.0413890743*APOBEC2*21.0 ± 23.0989.5 ± 1067.747.00.0017cg175487355′UTR;1stExon24.9 ± 2.528.9 ± 2.74.00.033cg223756101stExon12.8 ± 1.416.6 ± 1.73.90.0266840092*MYLPF*213.4 ± 492.611507.5 ± 4592.853.90.0017cg08130222TSS20054.8 ± 3.350.3 ± 3.3−4.50.044cg09762897Body10.3 ± 0.412.9 ± 1.02.60.0491070541*MYH3*200.9 ± 412.011286.7 ± 4171.656.20.0017cg06891639TSS150063.1 ± 2.855.6 ± 3.0−7.50.0496900360*MYH7*43.8 ± 63.24070.3 ± 2705.093.00.0017cg22963791Body10.8 ± 0.513.3 ± 1.02.50.0496620035*CASQ2*43.8 ± 60.14288.1 ± 2746.697.80.0017cg17903306TSS20070.0 ± 3.358.8 ± 3.3−11.20.0493610402*SLN*24.4 ± 8.92969.5 ± 3289.5121.60.0025cg09773458TSS150028.8 ± 2.735.0 ± 1.86.30.035Data are presented as mean ± SD

We then performed correlation analyses between expression and methylation of corresponding CpG sites for the 4285 genes that had significant differences in both (Additional file [4](#MOESM4){ref-type="media"}: Table S3). Here, we found 1236 and 998 correlations between expression and methylation in myoblasts and myotubes, respectively (Additional file [4](#MOESM4){ref-type="media"}: Table S3), which is more than expected by chance based on χ^2^ tests (688 correlations with *P* \< 0.05).

Using a luciferase assay, we continued to functionally study if DNA methylation affects the transcriptional activity of a gene that exhibits both differential methylation and expression during myogenesis. *MCM10*, which encodes a maintenance protein involved in DNA replication, was selected for this experiment as it showed increased methylation of several sites in the promoter region together with decreased expression after differentiation (Fig. [3h](#Fig3){ref-type="fig"}). A CpG-free luciferase expression vector containing 2000 bp of the *MCM10* promoter was either methylated in vitro with *SssI* or mock-methylated and transfected into cells. In line with our myotube data, we found that methylation of the *MCM10* promoter resulted in decreased transcriptional activity (Fig. [3i](#Fig3){ref-type="fig"}).

Functional follow-up experiments identified IL-32 as a novel regulator of myogenesis and insulin sensitivity {#Sec15}
------------------------------------------------------------------------------------------------------------

Although it is well established that some key proteins regulate the myogenesis in human muscle cells \[[@CR4]\], we hypothesized that there may be some additional proteins, not yet discovered, affecting the differentiation of myoblasts into myotubes and consequently muscle cell function. Genes previously not known to affect myoblast differentiation and which showed both altered expression and DNA methylation during myogenesis were therefore selected for functional follow-up studies.

The first selected candidate gene, *IL32* (encoding the cytokine Interleukin (IL)-32), showed a large increase in expression together with altered methylation in human myotubes compared with myoblasts (Fig. [4a](#Fig4){ref-type="fig"}).Fig. 4Silencing of *IL32* influences differentiation capacity and insulin signaling whereas *IL32* overexpression in mice impairs insulin sensitivity. **a** Array data of mRNA expression and DNA methylation (only significant sites) of *IL32* before versus after differentiation of primary human myoblasts from non-obese subjects (*n* = 13, \**q* \< 0.05). **b** Protein expression of IL-32 in primary human myoblasts (0 h) and after 3 and 7 days of differentiation. Stain-free total protein staining was used for normalization. A representative blot is shown above the bars (*n* = 7). **c** Increased protein level of IL-32 found during differentiation was significantly blocked with siRNA after 3 and 7 days of differentiation of myoblasts. The average of Si-SCR is set to 1 at both time points. Stain-free total protein staining was used for normalization. Representative blots are shown above the bars. **d** Significantly enriched gene sets in Gene Set Enrichment Analysis (GSEA) based on differential gene expression in IL-32 deficient myotubes (day 7) versus control (si-SCR). Lower panels show expression of genes contributing to the gene sets Hypertrophic Cardiomyopathy HCM and Pentose Phosphate Pathway (*n* = 5, \**q* \< 0.05). **e** A number of genes involved in myogenesis and metabolism with significantly different expression between IL-32 deficient myotubes (day 7) and control (*n* = 5, \**q* \< 0.05). Silencing of *IL32* was associated with increased levels of ATP (**f**) and increased insulin-stimulated AKT phosphorylation at Ser473 and Thr308 (*n* = 3) (**g**) in differentiated myotubes (day 7). **h** The expression of *IL32* in skeletal muscle biopsies obtained from 27 adult men correlated positively with HOMA-IR (Pearson correlation). **i** Experimental set-up of the mouse study with *IL32*tg mice showing the duration of HFD, including time points for different analyses. **j** There was no difference in body weight between *IL32*tg and WT mice after 18 weeks on a HFD. *IL32*tg mice had significantly lighter tibialis anterior in absolute value (**k**) and in relation to body weight (**l**) compared to WT after 18 weeks on a HFD. *IL32*tg mice had lower glucose levels in the fasted state and higher levels 20 minutes after intravenous insulin administration compared with WT (**m**), resulting in a decreased insulin response (**n**). **o** Significantly enriched gene sets in GSEA based on differential gene expression in tibialis anterior from *IL32*tg versus WT mice after 18 weeks on a HFD (*n* = 6). **p** Soleus from *IL32*tg mice have decreased Akt phosphorylation at Thr308 after 30 minutes in vitro incubation with or without insulin (WT *n* = 4, *IL32*tg *n* = 5). Data are presented as mean ± SEM, *n* = 4 for cell experiments, *n* = 10 for WT mice, and *n* = 9 for *IL32*tg mice if nothing else stated. WT, Wild type mice (control); *IL32*tg, *IL32* transgenic mice; HFD, High fat diet; \* *P* \< 0.05, \*\* *P* \< 0.01, \*\*\* *P* \< 0.001 for figure **b** and **e**--**o**. Statistics were calculated with paired t-test for cell experiments and Mann--Whitney U test for mice data

IL-32 has previously been implicated in inflammatory diseases and cancer, but its role in myogenesis or muscle function remains unknown \[[@CR34]\]. We next evaluated how the mRNA and protein expression patterns of IL-32 changed over time during differentiation of myoblasts into myotubes. Here, we found a significant increase in IL-32 expression 3 days after induction of differentiation and then a further increase after 7 days of differentiation (Fig. [4b](#Fig4){ref-type="fig"} and Additional file [1](#MOESM1){ref-type="media"}: Figure S2A). To assess whether IL-32 affects myogenesis or muscle function, we transfected primary human myoblasts with siRNA against *IL32* upon induction of differentiation. The cells were harvested at three time points -- at 0 hours and 3 or 7 days after start of differentiation and siRNA transfection. An overview of the siRNA experiment is shown in Additional file [1](#MOESM1){ref-type="media"}: Figure S2B. Silencing of *IL32* resulted in significantly decreased IL-32 mRNA and protein levels both 3 and 7 days after transfection with siRNA (Fig. [4c](#Fig4){ref-type="fig"} and Additional file [1](#MOESM1){ref-type="media"}: Figure S2C).

We continued to investigate the effects of *IL32* silencing on gene expression using microarray analysis. We found 1231 unique genes that were differentially expressed between *IL32* silenced myotubes and cells treated with non-targeting siRNAs (si-SCR) (*q* \< 0.05, Additional file [5](#MOESM5){ref-type="media"}: Table S4). We then applied GSEA and among the significant upregulated gene sets were several muscle-specific pathways (Fig. [4d](#Fig4){ref-type="fig"} and Additional file [5](#MOESM5){ref-type="media"}: Table S4). We also found increased expression of *MYOD1* and *MEF2C* as well as several MHCs and MLCs in *IL32* silenced cells (Fig. [4e](#Fig4){ref-type="fig"}), suggesting a negative role for IL-32 in myogenesis. Additionally, downregulated gene sets were related to amino acid and nucleotide turnover (Fig. [4d](#Fig4){ref-type="fig"} and Additional file [5](#MOESM5){ref-type="media"}: Table S4). Interestingly, a number of genes involved in ATP generation, e.g., in the citric acid cycle, the respiratory chain as well as creatine kinases were also upregulated, together with *PPARGC1A*, a transcriptional regulator of genes influencing energy metabolism (Fig. [4e](#Fig4){ref-type="fig"}).

As the microarray data indicated metabolic alterations in the *IL32* silenced cells, we proceeded to dissect the impact of IL-32 in myotubes. In line with our microarray data, we found increased ATP levels in *IL32* silenced cells (Fig. [4f](#Fig4){ref-type="fig"}). Moreover, IL-32-deficient myotubes exhibited increased insulin-stimulated AKT phosphorylation, as a measure of insulin sensitivity, at serine 473 (Ser473) and threonine 308 (Thr308) compared to control cells (si-SCR) (Fig. [4g](#Fig4){ref-type="fig"}). There was also a trend towards increased AKT phosphorylation at Thr308 at baseline (*P* = 0.11) (Fig. [4g](#Fig4){ref-type="fig"}). However, we could not detect any differences in glycogen synthase or TBC1D4 phosphorylation levels (data not shown).

These in vitro data in myotubes propose that IL-32 may contribute to impaired insulin sensitivity and metabolism. We subsequently tested if *IL32* expression in human skeletal muscle biopsies correlates with measures of insulin sensitivity analyzed in vivo using HOMA-IR in a cohort previously described \[[@CR17]\]. Interestingly, *IL32* expression in muscle biopsies taken from middle-aged healthy men correlated positively with HOMA-IR (Fasting glucose (mmol/L) × Fasting insulin (mU/L)/22.5), further supporting a negative impact of IL-32 on insulin sensitivity (Fig. [4h](#Fig4){ref-type="fig"}).

To better understand the function of IL-32 on muscle growth and insulin sensitivity in vivo, we used transgenic mice expressing human *IL32* in skeletal muscle as well as other tissues \[[@CR35]\]. *IL32* transgenic (*IL32*tg) and control (WT) mice were fed a Paigen high fat diet (HFD) \[[@CR36]\] or control diet for 18 weeks, after which tibialis anterior and soleus muscle were excised; Fig. [4i](#Fig4){ref-type="fig"} shows the design of the mouse study. Despite similar body weight, *IL32*tg mice had significantly lighter tibialis muscle than WT after 18 weeks on HFD, both in absolute and relative terms (Fig. [4j--l](#Fig4){ref-type="fig"}). Moreover, *IL32*tg mice on HFD had significantly higher glucose levels and responded less well to insulin after a 20 minutes insulin tolerance test versus WT (Fig. [4m, n](#Fig4){ref-type="fig"}). On the other hand, their fasting glucose levels were reduced. No differences in muscle weight or insulin sensitivity were observed for mice on control diet (data not shown), nor were any differences in glucose levels observed during an oral glucose tolerance test or in food intake in any of the groups (data not shown).

We proceeded to investigate gene expression in tibialis anterior from *IL32*tg and WT mice on a HFD by microarray. We found 1821 unique genes that were differentially expressed with *P* \< 0.05, but none with *q* \< 0.05 (Additional file [5](#MOESM5){ref-type="media"}: Table S4), including *MYH2*, *TNNT3*, and *CKMT2*. GSEA revealed oxidative phosphorylation, citric acid cycle and pyruvate metabolism among significantly downregulated gene sets in *IL32*tg mice (Fig. [4o](#Fig4){ref-type="fig"} and Additional file [5](#MOESM5){ref-type="media"}: Table S4), which is in line with human myotube data where *IL32*-deficient cells had increased OXPHOS gene expression and ATP levels. Also in line with human myotube data, ribosome was the only upregulated gene set in *IL32*tg mice (Fig. [4o](#Fig4){ref-type="fig"} and Additional file [5](#MOESM5){ref-type="media"}: Table S4).

To further follow-up our AKT findings in human myotubes and the impaired insulin sensitivity in *IL32*tg mice, fresh soleus muscles from mice in each group were incubated in vitro for 30 minutes with and without insulin. *IL32*tg mice on HFD showed decreased Akt phosphorylation at Thr308 both with or without insulin stimulation (Fig. [4p](#Fig4){ref-type="fig"}), which is in accordance with our human myotube data (Fig. [4g](#Fig4){ref-type="fig"}). However, we could not detect any differences in Akt phosphorylation at Ser473 or ATP levels in soleus between the groups (data not shown).

In summary, these in vitro and in vivo experiments from both human and mouse support IL-32 as a novel player affecting myogenesis and muscle function.

Another novel candidate gene, *ARPP21* (encoding cAMP-regulated phosphoprotein), was selected for functional follow-up experiments based on its massive upregulation and altered methylation in myotubes compared to myoblasts (Additional file [1](#MOESM1){ref-type="media"}: Figure S2D). *ARPP21* showed a modest but significant increase in expression 3 days after induction of differentiation and then a dramatic increase after 7 days of differentiation (Additional file [1](#MOESM1){ref-type="media"}: Figure S2E). To study the influence of ARPP-21 on myogenesis, we used the same siRNA silencing set-up as for *IL32* but with fewer read-outs as presented in Additional file [1](#MOESM1){ref-type="media"}: Figure S2B. Silencing of *ARPP21* reduced *MYOG* expression at day 3 of differentiation and reduced *TNNI1* (encoding Troponin I Type 1) expression levels both at days 3 and 7 (Additional file [1](#MOESM1){ref-type="media"}: Figure S2F-G), proposing that the increased *ARPP21* expression during late myogenesis may function to stimulate structural proteins like troponin.

Two additional candidate genes, *SMAD6* and *PLAC8*, were selected for follow-up experiments based on their massive downregulation and altered methylation during myogenesis (Additional file [1](#MOESM1){ref-type="media"}: Figure S2H, I). Here, we used siRNA to study whether reduced expression of SMAD6 and PLAC8 in myoblasts affects proliferation, initiation of myogenesis, and/or myotube function (Additional file [1](#MOESM1){ref-type="media"}: Figure S2J). However, silencing the expression of these genes in our primary muscle cells only affected a few studied phenotypes (Additional file [1](#MOESM1){ref-type="media"}: Figure S2K, L).

Impact of obesity on the DNA methylation pattern during differentiation of primary human myoblasts into myotubes {#Sec16}
----------------------------------------------------------------------------------------------------------------

Although recent studies suggest that obesity impairs myogenesis in rodents, there is limited data from myoblast differentiation in obese humans \[[@CR37]\]. We therefore investigated whether obesity affects the DNA methylation pattern during differentiation of primary human myoblasts into myotubes. The DNA methylation data described above in healthy non-obese subjects were compared with data from myoblasts and differentiated myotubes from 14 obese subjects (BMI \> 30 kg/m^2^; Fig. [1a](#Fig1){ref-type="fig"}). The clinical characteristics of these subjects are presented in Table [1](#Tab1){ref-type="table"}. Obese subjects had increased fat mass and insulin resistance estimated by HOMA-IR, as well as decreased HDL levels and VO~2max~, demonstrating a marked lower aerobic fitness level, compared with healthy non-obese subjects.

The average degree of DNA methylation was not significantly different between obese and non-obese subjects, neither in myoblasts nor in myotubes. Accordingly, the global methylation level increased in the same gene and CpG island regions in both obese and non-obese subjects after differentiation (Additional file [1](#MOESM1){ref-type="media"}: Figure S3A). However, among obese subjects, we identified 147,161 individual CpG sites with significantly altered DNA methylation in myoblasts versus myotubes (q \< 0.05, Additional file [6](#MOESM6){ref-type="media"}: Table S5), which is approximately 3.7 times more than for non-obese subjects (*P* ~χ2~ \< 0.001) where 39,572 CpG sites changed significantly during myogenesis (Fig. [1a](#Fig1){ref-type="fig"}). 103,829 (71%) of the significant sites in obese subjects had increased methylation and 43,332 (29%) had decreased methylation in myotubes compared with myoblasts (Additional file [1](#MOESM1){ref-type="media"}: Figure S3B).

The overlap of significantly changed CpG sites between the obese and non-obese groups was 27,388 for sites with increased methylation and 1645 for sites with decreased methylation (Fig. [5a](#Fig5){ref-type="fig"}), revealing a large number of CpG sites uniquely methylated/demethylated in either of the groups during myogenesis (Additional file [7](#MOESM7){ref-type="media"}: Table S6). Significant pathways enriched for all differentially methylated genes in obese subjects are presented in Table [2](#Tab2){ref-type="table"}.Fig. 5Differences in DNA methylation and gene expression before versus after differentiation of human primary myoblasts of obese and non-obese subjects. **a** Overlap of significant CpG sites with decreased and increased DNA methylation, respectively, after differentiation of human primary myoblasts of non-obese (*n* = 14) and obese (*n* = 14) subjects. **b** Significantly enriched gene ontology (GO)-terms (*q* \< 0.05) of genes that exhibit differential DNA methylation only in obese. **c** Distribution of significant CpG sites that showed differential DNA methylation during myogenesis in non-obese and obese subjects compared with all analyzed CpG sites on the array and also between non-obese and obese in relation to gene regions, CpG island regions, and enhancer-regions. \* *P* ~χ2~ \< 0.05 compared with all analyzed, \# *P* ~χ2~ \< 0.05 between non-obese and obese subjects. **d** Overlap of downregulated and upregulated genes during myogenesis between non-obese (*n* = 13) and obese subjects (*n* = 13). Networks of certain genes only differentially expressed during myogenesis in obese (**e**) and non-obese (**f**) subjects, respectively, and related GO-terms to these genes. Green, downregulated; red, upregulated. Node size is based on expression fold change. **g** Genes (different probes) regulated in opposite directions during myogenesis in non-obese and obese subjects (\* *q* \< 0.05). **h** The top graph shows mRNA expression of genes only differentially expressed and methylated in obese subjects during myogenesis that are associated with DNA methylation, obesity, and/or metabolic disorders as well as myogenesis and/or myopathies. Values are presented as log2 to reduce magnitude and better visualize expression of all genes grouped in each category in one graph. The lower graph shows DNA methylation of significant CpG sites annotated to genes with a red box in the top graph (\* *q* \< 0.05). **i** Significant enrichment of the number of CpG sites within obesity candidate genes with differential DNA methylation at *P* \< 0.05 between non-obese and obese subjects in myoblasts and myotubes, respectively (\* *P* ~χ2~ \< 0.05). Data are presented as mean ± SEM

We proceeded to identify unique genes where the methylation level only changed in obese or non-obese subjects during myogenesis. Here, one needs to take into account that different CpG sites in the same gene can change in the obese and/or non-obese subjects during differentiation, but this still represents the same gene in both groups. Thus, 5837 unique genes were differentially methylated during myogenesis only in the obese. Interestingly, these genes were significantly enriched in gene ontology (GO)-biological processes related to the immune response (Fig. [5b](#Fig5){ref-type="fig"} and Additional file [7](#MOESM7){ref-type="media"}: Table S6). The fact that epigenetic regulation is abnormal in cells from obese subjects, even after culturing them in the same condition as cells from non-obese subjects, demonstrates an altered epigenetic memory in muscle stem cells due to obesity. Methylation of 170 unique genes changed only in non-obese, but no enriched GO-biological process was found for these genes. To get a better view of where in the genome significant changes in methylation took place, the number of significant sites for each gene region was compared with the total number of analyzed sites for each region. In both obese and non-obese subjects, a higher proportion of significant sites than expected was observed in areas close to promoter regions, TSS, and CpG islands (*P* ~χ2~ \< 0.001; Fig. [5c](#Fig5){ref-type="fig"}). Nevertheless, obese subjects had a lower proportion than non-obese in TSS1500, TSS200, 5'UTR, 1^st^ exon, and CpG islands as well as a higher proportion in the gene body, 3'UTR, intergenic region, shelves, and open sea (*P* ~χ2~ \< 10^−11^). Additionally, 33,854 (23%) of the significant CpG sites in obese subjects were annotated to enhancer regions (Fig. [5c](#Fig5){ref-type="fig"}), which is significantly more than expected (*P* ~χ2~ \< 10^−104^). In non-obese subjects, there were 10,194 (26%) significant CpG sites annotated to enhancer regions, which is also more than expected (*P* ~χ2~ \< 10^−125^) and a higher proportion than in obese subjects (*P* ~χ2~ \< 10^−29^). The overrepresentation of significant CpG sites located in enhancer regions suggests that DNA methylation impacts on gene transcription during myogenesis.

Regarding non-CpG methylation in the obese, also here the number of significant sites was more than in non-obese subjects; 822 non-CpG sites (82%) had significantly changed methylation after differentiation (Additional file [6](#MOESM6){ref-type="media"}: Table S5).

Impact of obesity on the transcriptome during differentiation of primary human myoblasts into myotubes {#Sec17}
------------------------------------------------------------------------------------------------------

We proceeded to investigate if obesity affects the gene expression pattern during differentiation of primary human myoblasts into myotubes. Here, we compared the gene expression data described above in non-obese subjects with that of myoblasts and differentiated myotubes from 13 obese subjects (BMI \> 30 kg/m^2^). The expression level of 7362 transcripts corresponding to 6080 unique genes changed significantly before versus after differentiation in obese subjects (Additional file [8](#MOESM8){ref-type="media"}: Table S7), which is slightly less than in non-obese subjects (Fig. [1a](#Fig1){ref-type="fig"}). 40% of the significantly changed transcripts in obese subjects were upregulated and 60% were downregulated. Of note, all identified MRFs, MLCs, and MHCs with differential expression in non-obese subjects also changed in the same direction in the obese (Fig. [2a, e](#Fig2){ref-type="fig"} and Additional file [8](#MOESM8){ref-type="media"}: Table S7), except for *MYL5*, which was significantly upregulated only in non-obese subjects.

GSEA of differentially expressed genes in obese subjects resulted in 15 downregulated gene sets and 17 upregulated gene sets (Additional file [8](#MOESM8){ref-type="media"}: Table S7). While all enriched gene sets for obese were also enriched for non-obese subjects, a number of upregulated gene sets including tight junctions, calcium signaling, and metabolism of various fatty acids as well as two downregulated gene sets -- galactose metabolism and drug metabolism, other enzymes ﻿-- were only enriched in the non-obese (Fig. [2b, c](#Fig2){ref-type="fig"} and Additional file [3](#MOESM3){ref-type="media"}: Table S2), suggesting that partial loss of muscle cell function occurs in obese humans.

Interestingly, we identified numerous unique changes in expression during myogenesis between obese and non-obese subjects, i.e., 1151 genes were only differentially expressed in obese and not in non-obese subjects, while 1376 genes only changed expression in the non-obese (Fig. [5d](#Fig5){ref-type="fig"} and Additional file [9](#MOESM9){ref-type="media"}: Table S8). Additionally, 2746 downregulated genes and 2191 upregulated genes after differentiation were overlapping between obese and non-obese subjects.

We next used GeneMANIA Cytoscape \[[@CR38], [@CR39]\] to visualize enriched biological processes associated with genes that only changed expression in either obese or non-obese subjects. Several GO-terms related to oxidative phosphorylation and an IL-1 response were significant only for obese subjects (Fig. [5e](#Fig5){ref-type="fig"} and Additional file [9](#MOESM9){ref-type="media"}: Table S8), whereas many GO-terms related to insulin signaling and glucose homeostasis were significant only for non-obese subjects (Fig. [5f](#Fig5){ref-type="fig"} and Additional file [9](#MOESM9){ref-type="media"}: Table S8). In contrast, GO-terms related to, e.g., the cell cycle, antigen recognition, and protein turnover were significant for both the unique genes found in either the obese or non-obese (Additional file [9](#MOESM9){ref-type="media"}: Table S8), suggesting a potential compensatory mechanism between genes uniquely regulated in the two groups. Interestingly, we also identified two genes, *PTP4A2* and *PDCD7*, which were significantly upregulated in the obese, while significantly downregulated in the non-obese during myogenesis (Fig. [5g](#Fig5){ref-type="fig"}). In contrast, *PSMA1*, *ST3GAL3*, and *C11orf58* (*SMAP*) were downregulated in obese while upregulated in non-obese subjects (Fig. [5g](#Fig5){ref-type="fig"}). Collectively, these data support metabolic and inflammatory disparities between differentiating muscle stem cells isolated from obese and non-obese subjects.

Overlapping differences in DNA methylation and mRNA expression during differentiation in obese versus non-obese subjects {#Sec18}
------------------------------------------------------------------------------------------------------------------------
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We then performed correlation analyses between the expression and methylation of corresponding CpG sites for the 5197 genes that had significant differences in both expression and methylation in obese subjects (Additional file [10](#MOESM10){ref-type="media"}: Table S9). Here, we found 3515 and 4014 correlations between expression and methylation in myoblasts and myotubes, respectively (Additional file [10](#MOESM10){ref-type="media"}: Table S9), which is more than expected by chance (2351 correlations with *P* \< 0.05).

Differential DNA methylation and gene expression in myoblast and/or myotubes between obese and non-obese subjects {#Sec19}
-----------------------------------------------------------------------------------------------------------------

We further tested if any individual CpG sites were differentially methylated when comparing myoblasts between obese and non-obese or when comparing myotubes between obese and non-obese, respectively. While 29,337 CpG sites were differentially methylated in myoblasts from obese versus non-obese at *P* \< 0.05, only methylation of two CpG sites (near *ZNF629* and *SDCCAG1*) were significantly different based on FDR \< 5% (Additional file [12](#MOESM12){ref-type="media"}: Table S11). In myotubes, 28,884 sites were differentially methylated between obese and non-obese subjects at *P* \< 0.05, but none had FDR \< 5%. Nevertheless, we proceeded to test if there was an over-representation of identified CpG sites with *P* \< 0.05 in/near known candidate genes for obesity based on discoveries in genome-wide association studies (*P* \< 1.0 × 10^−5^; [www.genome.gov/gwastudies](http://www.genome.gov/gwastudies) accessed 22 August 2012). Out of 3472 analyzed CpG sites annotated to 129 candidate genes for obesity, 273 CpG sites in 93 genes had differential methylation in obese versus non-obese at *P* \< 0.05 in myoblasts and 253 CpG sites in 86 genes had *P* \< 0.05 in myotubes (Fig. [5i](#Fig5){ref-type="fig"} and Additional file [12](#MOESM12){ref-type="media"}: Table S11). This is more than expected by chance (myoblasts; *P* ~χ2~ = 2.3 × 10^−5^, and myotubes; *P* ~χ2~ = 0.001), thus suggesting that epigenetic variation may influence the genetic risk for metabolic disorders \[[@CR40]\]. We continued to compare the transcriptome profile in myoblasts and myotubes from obese versus non-obese subjects. After FDR correction, there were no significant differences in gene expression between obese and non-obese subjects in myoblasts nor in myotubes. Neither did we find any enrichment of candidate genes for obesity among the genes with altered expression at *P* \< 0.05 between obese and non-obese subjects in myoblasts or myotubes.

Enzymes regulating DNA methylation in obese and non-obese subjects {#Sec20}
------------------------------------------------------------------

To further assess why methylation of approximately 3.7 times more sites changed in obese compared with non-obese subjects during differentiation, we analyzed the expression of all three catalytically active DNA methyltransferases (DNMTs) with qPCR at three different time points, in myoblasts and after 2 (intermediate) and 7 (myotubes) days of differentiation (Fig. [6a](#Fig6){ref-type="fig"}). Interestingly, *DNMT1* expression was only significantly upregulated in obese, but not in non-obese subjects, after 2 days of differentiation. The significant changes in the expression patterns for *DNMT3A* and *DNMT3B* were similar in obese and non-obese subjects (Fig. [6a](#Fig6){ref-type="fig"}).Fig. 6*DNMT1, DNMT3A*, and *DNMT3B* during differentiation of primary human myoblasts. **a** mRNA expression of *DNMT1, DNMT3A*, and *DNMT3B* in myoblasts, after 2 days of differentiation (intermediate) and in differentiated myotubes from six non-obese and six obese subjects. **b** siRNA silencing of *DNMT1* in the myoblasts was confirmed after 3 and 7 days of differentiation at mRNA and protein levels. The average of Si-SCR is set to 1 at both time points for protein expression. Stain-free total protein staining was used for normalization. Representative blots are shown above the bars. Silencing of *DNMT1* resulted in reduced expression of *cMYC* and *JUNB* after 3 days of differentiation (**c**) as well as increased expression of *MYOD1* (*n* = 7) (**d**) and reduced levels of ATP (*n* = 3) in myotubes (day 7) (**e**). Data are presented as mean ± SEM, *n* = 4 for (**b**--**e**) if nothing else stated, except protein levels in (**b**) at day 3, where *n* = 3. \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001

We next silenced *DNMT1* to further study its role during myogenesis (Additional file [1](#MOESM1){ref-type="media"}: Figure S2B) and reduced mRNA and protein levels were achieved after 3 and 7 days of differentiation (Fig. [6b](#Fig6){ref-type="fig"}). This resulted in reduced expression of two cell cycle regulators, *cMYC* and *JUNB*, after 3 days, as well as increased expression of the myogenic marker *MYOD1* and decreased ATP levels after 7 days, of differentiation (Fig. [6c--e](#Fig6){ref-type="fig"}). Hence, DNMT1 seems to affect myogenesis and cell function.

Differences in DNA methylation could potentially also be explained by differences in the availability of methyl groups or other epigenetic modifiers. Notably, the expression pattern of 10 enzymes and modifiers involved in the one carbon metabolism and generation of the methyl donor S-adenosylmethionine changed significantly in either the obese and non-obese during differentiation (Additional file [1](#MOESM1){ref-type="media"}: Figure S3C). These differences may also contribute to the abnormal methylation changes seen in the obese, i.e., that approximately 3.7 times more CpG sites changed in obese compared with non-obese subjects during myogenesis.

Secretion of cytokines and growth factors from myoblasts and myotubes of obese and non-obese subjects {#Sec21}
-----------------------------------------------------------------------------------------------------

Extracellular stimuli, like circulating cytokines and growth factors, influence myogenesis \[[@CR4]\], and their secretion may be altered by obesity. We therefore analyzed the secretion of CCL2, TGF-β3, IL-32, IL-6, and TNF-α, all previously implicated in myogenesis (except IL-32) \[[@CR41]\], in the culture media from myoblasts and myotubes of obese and non-obese subjects.

As expected, the secretion of CCL2 increased after differentiation in non-obese and correlated with its corresponding mRNA level in myoblasts (Additional file [1](#MOESM1){ref-type="media"}: Figure S3D). The same secretion pattern was seen for the obese. TGF-β3 was the cytokine with highest fold-change in mRNA expression between myoblasts and myotubes in both obese and non-obese subjects (Additional file [1](#MOESM1){ref-type="media"}: Figure S3E). However, significantly increased TGF-β3 secretion after differentiation was only observed in the obese (Additional file [1](#MOESM1){ref-type="media"}: Figure S3E). Thereby, we also identified a secretory discrepancy between myotubes generated from muscle stem cells of obese and non-obese subjects, although cultured under the same condition. IL-32 could not be detected in culture media from myoblasts (Additional file [1](#MOESM1){ref-type="media"}: Figure S3F), which is in agreement with the IL-32 data presented above (Fig. [4a, b](#Fig4){ref-type="fig"}). However, we could detect IL-32 secretion from myotubes from 46% of the non-obese and 20% of the obese subjects, suggesting that IL-32 may be a myokine. However, there was no significant difference in secretion levels between the obese and non-obese (Additional file [1](#MOESM1){ref-type="media"}: Figure S3F). No differences in secretion of IL-6 and TNF-α were detected (data not shown).

Technical and biological validation {#Sec22}
-----------------------------------

We finally tested if our microarray data could be technically and biologically validated. For technical validation, we compared our mRNA microarray data with qPCR data generated from the same samples for *DNMT1* and found significant correlations between the microarray and qPCR data (r = 0.57, *P* = 0.002). For biological validation, we compared our microarray data for *IL32* and *ARPP21* with qPCR data generated in a different set of cells cultured at different time points. Importantly, we found the same changes in the expression pattern for these two genes in cell culture experiments performed at different time points (Fig. [4a](#Fig4){ref-type="fig"}, Additional file [1](#MOESM1){ref-type="media"}: Figure S2A and D--E).

Discussion {#Sec23}
==========

This study highlights the importance of genome-wide epigenetic changes during human myogenesis. We found numerous epigenetic and transcriptional alterations during differentiation of primary human muscle stem cells. Importantly, we identified IL-32 as a novel factor influencing myogenesis and insulin sensitivity. Moreover, we observed abnormal epigenetic changes and gene expression patterns during differentiation of human muscle stem cells from obese compared with non-obese subjects.

Here, we present the first study analyzing the genome-wide DNA methylation and gene expression patterns during differentiation of activated primary muscle stem cells isolated from a large human cohort including both obese and non-obese subjects. We observed overwhelming de novo methylation during myogenesis, supporting DNA methylation as an important epigenetic mechanism coordinating cell-specific gene expression as the cells become more specialized. Importantly, myogenesis was accompanied by dynamic methylation and expression changes of *PAX7*, all major MRFs and MEF2s (*MYOD*, *MYF5*, *MYOG*, *MYF6*, *MEF2A*, *MEF2C*, M*EF2D*), the MHC and MLC families, as well as mitochondrial proteins, thereby demonstrating that the cells were successfully differentiated. Moreover, GSEA of genes differentially expressed following differentiation showed downregulation of gene sets involved in the cell cycle and DNA synthesis, reflecting that the myoblasts go into cell cycle arrest and start to differentiate. Upregulated gene sets reflect myofiber formation (e.g. hypertrophic cardiomyopathy, cardiac muscle contraction, and calcium signaling pathway) and support that the myotubes line up close to each other (extracellular matrix receptor interaction and cell adhesion), which can also be seen in the pictures of our differentiated myotubes. Interestingly, the GSEA revealed a major shift in metabolism and substrate choice, with the myoblasts having higher expression levels of gene sets regulating fructose, mannose and galactose metabolism, and the pentose phosphate pathway and the myotubes having higher expression levels of gene sets regulating fatty acid metabolism as well as tryptophan and linoleic acid metabolism. Altogether, this proposes a shift from using carbohydrates as fuels in dividing myoblasts towards using fatty acids and amino acids as fuels and building blocks in mature myotubes. This is in accordance with a recent study showing that activated satellite cells (myoblasts) rely on glycolysis \[[@CR42]\]. Ryall et al. \[[@CR42]\] further describe how a shift in metabolic substrate utilization, partly through histone modifications, regulates cell development and cell fate, a process termed 'metabolic reprogramming'. In our study, numerous changes in DNA methylation induced by differentiation accompany the shift in expression of gene sets regulating metabolism, thereby suggesting a close interaction between epigenetic modifications and metabolism during myogenesis.

Interestingly, two pregnancy-associated gene families, PSGs and CGBs, were among the most downregulated gene groups characterizing the transition from myoblast to myotube. The PSGs are glycoproteins secreted by the placental trophoblasts into the maternal bloodstream during pregnancy and are associated with fetal well-being \[[@CR29]\]. The CGBs are also secreted by the placental trophoblasts with the purpose of maintaining the corpus luteum during pregnancy \[[@CR30]\]. Neither the PSGs nor CGBs have ever been detected or described in relation to skeletal muscle, myoblasts, or myogenesis. However, from our studies, it seems as if they could have a major impact on human myoblast regulation. Another pregnancy associated protein, leukemia inhibitory factor, which is normally also expressed by trophoblasts to facilitate implantation, has in two decades been known to stimulate proliferation of myoblasts \[[@CR43]\], was tested for its effect of myoblast transplantation in animals \[[@CR44]\], and has been shown to be secreted from myoblasts \[[@CR45]\]. These findings indicate possible secretory similarity between trophoblasts and myoblasts. Another interesting gene group downregulated during myoblast differentiation is the metallothioneins, which also showed dynamic changes in DNA methylation during myogenesis. They have been sparsely described in relation to skeletal muscle, but appear to increase in atrophying muscles \[[@CR46]\] and might be related to a high requirement of zinc for metabolic activities during the early stage of myoblast differentiation \[[@CR47]\].

In addition to the identified novel gene groups described above, a number of unique genes displayed transcriptional and epigenetic changes, and could thus potentially be involved in regulating myogenesis and muscle function. We selected some of these novel candidate genes, including *IL32*, which was dramatically upregulated during differentiation, for functional follow-up experiments. By combining in vitro and in vivo experiments, IL-32 was found to have negative effects on both myogenesis and insulin sensitivity in mice and humans. Silencing *IL32* in human myotubes increased insulin-stimulated AKT phosphorylation and intracellular ATP levels. These cells also had increased expression of OXPHOS genes and *PPARGC1A*, which is in line with changes seen in muscle during exercise \[[@CR48], [@CR49]\]. To further explore this relationship in vivo, we studied mice overexpressing human *IL32* and fed a HFD. *IL32*tg mice responded less well to insulin, which resulted in higher glucose levels, had lower insulin-stimulated Akt phosphorylation in soleus, and decreased OXPHOS gene expression in tibialis anterior, supporting our in vitro data. We could not detect any alteration in ATP levels in soleus muscle from *IL32*tg mice, which may reflect that the phenotype is more pronounced in some muscle types or in pure muscle cells. Remarkably, we also found a negative association between muscle-derived *IL32* levels and whole body insulin sensitivity in humans in vivo. Our experiments further suggest that IL-32 has negative effects on myogenesis and muscle growth/maintenance by inhibiting expression of myogenic genes, potentially through reduced AKT signaling. For example, the expression of *MEF2C*, *MYOD1*, and *DMD* was higher in IL-32-deficient myotubes and *IL32*tg mice had decreased muscle mass. Upregulation of IL-32 during myogenesis may therefore function to inhibit muscle overgrowth. Even if muscle function and mass is of great importance for a good quality of life, the tissue is metabolically expensive. It may therefore have been evolutionary beneficial for survival to develop mechanisms that control muscle growth and reduce insulin sensitivity \[[@CR50]\], while with the modern lifestyle it contributes to disease. Interestingly, several of the effects of IL-32 on muscle cells resemble those of myostatin, a master regulator of muscle growth. Myostatin is a myokine, which increases during myogenesis, signals through the TGF-β pathway, and regulates myoblast differentiation \[[@CR51], [@CR52]\]. Increased expression of myostatin is associated with muscle wasting, while its knockdown causes hypertrophy. One of the mechanisms by which myostatin exerts its function is through reduced AKT phosphorylation. It also seems to regulate glucose utilization and its expression is positively correlated with insulin resistance \[[@CR53]\]. Myostatin inhibitors have been intensively studied as pharmaceutical targets for muscle atrophy and mice treated with anti-myostatin antibodies have increased muscle mass and improved muscle insulin sensitivity \[[@CR54]\]. In conclusion, our findings suggest that IL-32 resembles myostatin in several ways, warranting future studies on whether IL-32 inhibitors may improve muscle mass and function. We also demonstrate, for the first time, that IL-32 is secreted from myotubes, further encouraging studies of its function in muscle biology.

DNA methylation was initially considered a silencing mark. However, more recent data show that the impact of methylation on expression varies with genomic context and methylation may both negatively and positively affect the transcriptional activity, regulating splicing and use of alternative promoters \[[@CR33]\]. For example, the *IL32* promoter does not reside in a CpG island and increased methylation may therefore be observed together with increased expression. While large absolute changes in DNA methylation are observed in cancer cells, modest methylation changes are commonly seen in non-tumorigenic cells \[[@CR17], [@CR18], [@CR55]\]. Nevertheless, the effects may still be of biological relevance, particularly in complex diseases where numerous changes with smaller effect sizes are known to affect disease susceptibility \[[@CR56]\]. Here, we found both negative and positive correlations between expression and methylation for numerous genes in both myoblasts and myotubes, emphasizing the complexity of epigenetic regulation of expression as mentioned above. The luciferase assay further showed that increased promoter methylation directly influences the transcriptional activity of *MCM10*, whose expression and methylation changed during myogenesis.

Obesity is a complex, multifactorial disorder rapidly increasing worldwide. Although interactions between genetic and environmental factors are known to affect a person's susceptibility to weight gain, identified genetic variants do only explain a modest proportion of the estimated heritability of obesity and related diseases \[[@CR56]\]. This has resulted in a growing interest in understanding the role of epigenetics in the increasing prevalence of obesity. Indeed, obesity, overfeeding, physical activity, and genetic variation have been shown to alter the genome-wide DNA methylation pattern in human adult tissues \[[@CR17], [@CR18], [@CR57]--[@CR61]\]. However, current knowledge about the impact of obesity on the epigenetic pattern during differentiation of human stem cells remains scarce.

The novel observation of altered epigenetic and transcriptomic regulation during differentiation of myoblasts isolated from obese individuals shows that muscle stem cells are profoundly altered/programmed by the systemic nutritional environment and/or physical inactivity. Although the muscle stem cells from obese and non-obese subjects were cultured during identical conditions, the number of DNA methylation changes induced by differentiation was three-fold higher in the obese. This clearly demonstrates a different epigenetic reorganization during the transition from myoblast to myotube as a memory of the obese environment. DNMT1 is a methyltransferase known to maintain methylation during replication, but has also been found to affect de novo methylation during cell differentiation \[[@CR62], [@CR63]\]. Hence, the more active de novo methylation observed in cells from obese may be explained by the increased *DNMT1* expression in early myogenesis. We further silenced *DNMT1* throughout myogenesis and found decreased levels of *cMYC* and *JUNB* at day 3 of differentiation as well as increased *MYOD1* expression in differentiated myotubes, suggesting that DNMT1 may also affect the cell cycle and differentiation in these cells.

While approximately three times more methylation changes took place in the obese during differentiation, only a modest number of differences were observed in myoblasts from obese versus non-obese subjects. It may be explained by large variances within groups. Indeed, the phenotype of a complex disease is commonly caused by a combination of many small variations at numerous loci that require large cohorts for detection \[[@CR64]\].

A surprisingly large number of genes were uniquely changed in expression either in obese cells (1151) or non-obese cells (1376) after differentiation, underscoring that both DNA methylation and gene expression changes vary genome-wide between the two cell populations. Interestingly, several genes that only showed expression changes in the non-obese are known to regulate insulin signaling and glucose homeostasis. Indeed, the obese subjects included in this study were insulin resistant and had lower oxidative capacity based on VO~2max~. Among the genes that showed both differential gene expression and methylation in only obese, were genes previously associated with dysfunctional myogenesis, e.g., *PLCB1* and *CDK9* \[[@CR65], [@CR66]\], genes linked to obesity or other metabolic diseases, including *IL18*, *PNPLA2*, and *ENHO* \[[@CR67]--[@CR69]\], as well as genes for which an association to obesity has never been described. The latter may be interesting targets to study further in relation to obesity and myogenesis. Of interest are also five genes that were regulated in opposite direction in obese compared with non-obese. One of these, *PSMA1* has previously been associated with fatty liver in obese subjects \[[@CR70]\]. Additionally, *PTP4A2* was recently implicated in hematopoietic stem cell self-renewal \[[@CR71]\] and *PDCD7* encodes a component of the spliceosome \[[@CR72]\].

Conclusions {#Sec24}
===========

This study provides a comprehensive map of the dynamic methylome and transcriptome during differentiation of human muscle stem cells and identified numerous of new myogenic targets. Importantly, we showed that IL-32 is a novel candidate influencing human myogenesis and insulin sensitivity both in vivo and in vitro. Our data further highlight that the metabolic environment influences the epigenetic memory in human muscle stem cells, thereby altering the transcriptome and epigenome during adult myogenesis in obese individuals.
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